drugset / Trial / NCT06447506
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.
Non-randomizedParallel-groupDouble-blindTreatment
Summary
The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).
Timeline
- Start
- 2024-06-05
- Primary completion
- 2025-07-29
- Completion
- 2025-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK1070806 | Monoclonal antibody | — | Subcutaneous |